搜尋結果
Opinion | An Alzheimer’s Advance, Not a Cure-All
The Wall Street Journal· 6 日前Donanemab promises progress. The FDA shouldn’t hold out for perfection.
Forbes EQ BrandVoice: Autistic People More Likely To Identify As LGBTQ
Forbes· 2 日前One day, Riley Smith learned from some former co-workers that an acquaintance had come out as ...
Jim Cramer says Eli Lilly isn't a 'one trick pony' after FDA advisers endorse its ...
CNBC· 4 日前CNBC's Jim Cramer on Tuesday explained why he continues to be bullish about pharmaceutical ...
Even Though Musk Got The Votes, He Won't See $50 Billion For A Long Time
Forbes· 2 日前Legal experts weigh in on what steps Tesla and Musk could take after Tesla shareholders vote ...
Teladoc Health BrandVoice: GLP-1 End Game: Should Deprescribing Be The Goal?
Forbes· 1 日前The early stages of any new, clinically impactful drug put pressure on benefit leaders. While ...
Things You Should Know About Adenoviruses
Forbes· 3 日前Once perceived as mere pathogens, adenoviruses have transformed remarkably, becoming ...
Biotech Insiders Share Five Lessons From Pioneering New Medicines
Forbes· 5 日前Last week, I had the good fortune of attending the BIO International Convention in San Diego, Calif., where more than 18,500 ...
Alzheimer’s Disease Drug Donanemab Gets Unanimous Backing From FDA Expert Panel
Forbes· 4 日前A Food and Drug Administration expert panel of advisors voted 11-0 yesterday to recommend that ...
How To Spend Three Days In Mallorca
Forbes· 5 日前Mallorca, the largest of the Balearic Islands off eastern Spain, has long attracted visitors ...
What To Eat And Do In Mauritius, As A Foodie
Forbes· 2 日前Mauritius, the vibrant island nation just east of Africa, offers much more than sandy beaches ...